Global Drug Eluting Balloon for Peripheral Artery Disease Market Size By Type (3μg/ mm2, 2μg/ mm2), By Application (Hospitals, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2023 to...

The Global Drug Eluting Balloon for Peripheral Artery Disease Market was valued at USD 612.5 million in 2023 and is projected to reach USD 1,325.4 million by 2031, growing at a compound annual growth rate (CAGR) of 10.2% during the forecast period from 2023 to 2031. This market is witnessing significant expansion due to the rising prevalence of peripheral artery disease (PAD), increasing demand for minimally invasive treatment options, and strong clinical outcomes associated with drug eluting balloon (DEB) technologies. The shift towards DEBs is also driven by their ability to reduce restenosis rates and eliminate the need for permanent implants, making them an effective alternative to traditional stents.

Drivers:

1. Growing Incidence of Peripheral Artery Disease:

The global burden of PAD continues to rise, especially among the aging population and individuals with diabetes and smoking habits. This epidemiological trend directly boosts the demand for effective treatment modalities like DEBs.

2. Advantages Over Traditional Stenting:

Drug eluting balloons offer the benefit of localized drug delivery without leaving a permanent implant, thus lowering the risk of thrombosis and reducing long-term complications.

3. Technological Advancements in Drug Coating:

Improvements in coating technologies, including the development of newer antiproliferative agents and excipients, enhance drug retention and transfer efficiency, boosting the therapeutic efficacy of DEBs.

Restraints:

1. High Cost of DEB Procedures:

The relatively higher costs of DEB systems compared to plain balloon angioplasty or bare-metal stents can be a limiting factor, particularly in cost-sensitive healthcare settings.

2. Limited Reimbursement in Developing Markets:

In many developing countries, lack of comprehensive reimbursement for DEB procedures poses a challenge to wider adoption, slowing down market penetration.

Opportunity:

1. Untapped Potential in Emerging Economies:

Asia-Pacific and Latin America present substantial growth opportunities due to improving healthcare infrastructure, rising healthcare awareness, and expanding access to advanced endovascular procedures.

2. Expanding Indications and Research Initiatives:

Ongoing clinical research exploring the use of DEBs in treating other vascular conditions, including below-the-knee lesions and in-stent restenosis, offers potential for product innovation and market expansion.

Market by System Type Insights:

Based on system type, the Paclitaxel-based DEBs segment held the largest market share in 2023. These DEBs are widely adopted due to extensive clinical validation and robust efficacy in preventing restenosis. However, the Sirolimus-based DEBs segment is anticipated to witness the fastest growth rate over the forecast period, driven by emerging evidence supporting better safety profiles and anti-inflammatory benefits.

Market by End-use Insights:

In terms of end-use, the Hospitals segment emerged as the dominant revenue generator in 2023, driven by the high number of PAD interventions conducted in inpatient settings. Ambulatory Surgical Centers (ASCs) are expected to grow rapidly due to the trend toward outpatient procedures and the rising availability of minimally invasive technology.

Market by Regional Insights:

North America led the global DEB market in 2023, supported by advanced healthcare infrastructure, favorable reimbursement policies, and high awareness of PAD treatments. Meanwhile, Asia-Pacific is projected to register the fastest growth rate, fueled by a surge in PAD cases, expanding geriatric population, and increasing adoption of endovascular therapies in countries like China, India, and South Korea.

Competitive Scenario:

Key players in the Global Drug Eluting Balloon for Peripheral Artery Disease Market include Medtronic plc, Boston Scientific Corporation, B. Braun Melsungen AG, Biotronik SE & Co. KG, Abbott Laboratories, Cook Medical, Concept Medical, Inc., Surmodics, Inc., BD (Becton, Dickinson and Company), and Terumo Corporation. These companies are focusing on expanding their product portfolios, engaging in strategic collaborations, and gaining regulatory approvals to strengthen their market presence.

Scope of Work – Global Drug Eluting Balloon for Peripheral Artery Disease Market

Report Metric Details

Market Size (2023) USD 612.5 million

Projected Market Size (2031) USD 1,325.4 million

CAGR (2023–2031) 10.2%

Market Segments By System Type (Paclitaxel-based, Sirolimus-based), By End-use (Hospitals, ASCs)

Growth Drivers Rising PAD prevalence, Advantages over stents, Technology innovation

Opportunities Emerging markets, New indications for DEBs

Key Market Developments:

2023: Boston Scientific expanded its portfolio by launching a new-generation drug eluting balloon featuring optimized drug-release kinetics and enhanced catheter delivery design.

2024: Concept Medical received FDA breakthrough designation for its sirolimus-coated balloon, indicating regulatory momentum for newer DEB types.

2025: Medtronic entered into a collaboration with a major vascular institute to conduct a multi-center study on DEBs for below-the-knee PAD, targeting improved outcomes in complex lesions.

FAQs:

1) What is the current market size of the Global Drug Eluting Balloon for Peripheral Artery Disease Market?

The market was valued at USD 612.5 million in 2023.

2) What is the major growth driver of the Global Drug Eluting Balloon for Peripheral Artery Disease Market?

The major driver is the growing incidence of peripheral artery disease and the increasing preference for minimally invasive treatments.

3) Which is the largest region during the forecast period in the Global Drug Eluting Balloon for Peripheral Artery Disease Market?

North America is expected to maintain its lead as the largest region.

4) Which segment accounted for the largest market share in the Global Drug Eluting Balloon for Peripheral Artery Disease Market?

The Paclitaxel-based DEB segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Drug Eluting Balloon for Peripheral Artery Disease Market?

Major players include Medtronic, Boston Scientific, Biotronik, Abbott, and B. Braun.